Summary of SKIN Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $72.1 million, down 7.8% year-over-year, at the lower end of guidance.

Equipment Sales: $18.3 million, down 18.4% with 770 systems placed (compared to 957 in the prior year).

Consumables Revenue: $53.9 million, down 3.5%, impacted by lower utilization and tough comparisons from the previous year.

Adjusted EBITDA: $17 million, up from $13.9 million in the prior year, exceeding guidance of $11 million to $13 million.

GAAP Gross Margin: 68.4%, improved from 62.8% year-over-year; adjusted gross margin at 71.8%, up from 65.9%.

Net Loss: $2.7 million, compared to net income of $19.7 million in the prior year (which included an $18.1 million gain from debt transactions).

Cash Position: Approximately $26 million, slightly above the previous quarter.

2Strategic Updates and Business Highlights

Core Strategy: Focus on strengthening the HydraFacial franchise, increasing the value of existing systems, and expanding into adjacent categories.

New Initiatives:

Launched a device rental program to reduce upfront costs for providers, aimed at expanding the installed base.

Continued development of the next-generation HydraFacial platform, targeting a 2028 launch.

Upcoming clinically validated boosters and the relaunch of HydraScalp to enhance treatment options and utilization.

Installed Base Growth: Increased to 36.5 thousand systems globally, up 3.8% year-over-year, with 75% of revenue derived from recurring consumables.

3Forward Guidance and Outlook

Revenue Outlook: Reduced to $280 million to $290 million for the year, reflecting ongoing pressure on device sales.

Adjusted EBITDA Guidance: Increased to $39 million to $46 million, up from a previous range of $35 million to $45 million.

Q3 Expectations: Revenue projected between $65 million to $70 million, with adjusted EBITDA of $5 million to $7 million.

R&D Investment: Expected increase of $4 million in the second half of the year.

4Challenges and Points of Concern

Revenue Decline: Overall revenue pressure noted across domestic and international markets, particularly in equipment sales.

Market Conditions: Providers are cautious about capital investments, impacting equipment sales.

Competitive Landscape: Intensifying competition with aggressive pricing and commercial incentives from competitors.

NASDAQ Compliance: Received notice for trading below the minimum bid price; plans for a reverse stock split to maintain compliance.

5Notable Q&A Insights

Consumer Behavior: Consumers are diversifying their spending across more treatment options, affecting consumables utilization. The company sees this as an opportunity to enhance treatment frequency.

Rental Program: Designed to address capital constraints for providers, expected to expand the addressable market without cannibalizing existing sales.

Payback Period for Equipment: Generally around 9 months, influenced by treatment volume.

Skin Stylus Performance: Notable growth of nearly 50% year-over-year attributed to focused sales efforts.

Future Device Launches: Plans to introduce a new device in 2027, with ongoing development for clinically validated boosters. Overall, while SKIN faces significant challenges in revenue growth and competitive pressures, it is strategically positioning itself for long-term growth through innovation and improved provider engagement.